Monte Rosa Therapeutics, Inc. (GLUE)
| Market Cap | 867.64M+37.8% |
| Revenue (ttm) | 28.73M |
| Net Income | -161.12M |
| EPS | -1.75 |
| Shares Out | 85.31M |
| PE Ratio | n/a |
| Forward PE | -5.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,080,592 |
| Open | 9.84 |
| Previous Close | 9.87 |
| Day's Range | 9.68 - 10.75 |
| 52-Week Range | 7.64 - 25.77 |
| Beta | 1.37 |
| Analysts | Strong Buy |
| Price Target | 28.00(+175.32%) |
| Earnings Date | Nov 5, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About GLUE
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$GLUE stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in GLUE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by GLUE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
GLUE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
GLUE Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Other development and discovery programs | $9.80M | 37.10% |
| Collaboration Revenue | $8.97M | 33.96% |
| Interest and other income, net | $5.94M | 22.50% |
| Professional services | $1.70M | 6.45% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New GLUE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to GLUE from public contracts
Source: USAspending.gov
GLUE Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from GLUE’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score